What do you know about Richard Ebright
Answers
Ebright was appointed as a faculty member in the Department of Chemistry at Rutgers University and as a Laboratory Director at the Waksman Institute of Microbiology in 1987.[1] He was co-appointed as an Investigator of the Howard Hughes Medical Institute from 1997 to 2013.[1]
Ebright has performed research on protein-DNA interaction,[3][4][5]transcription initiation,[6][7][8][9][10][11][12]transcription activation,[13][14][15][16][17][18] transcription-translation coupling,[19] and antibacterial drug discovery.[20][21][22][23][24][25] Ebright's research results include the experimental demonstration that amino-acid-base contacts mediate DNA sequence recognition in protein–DNA interaction,[3] the determination of the three-dimensional structural organization of the transcription initiation complex;[6][7][10][11] the demonstration that transcription start-site selection and initial transcription involve a "DNA scrunching" mechanism;[8][9][12] the demonstration that transcription activation can proceed by a "recruitment" mechanism;[13][14][15][17][18] the demonstration that bacterial transcription-translation coupling involves direct physical bridging of RNA polymerase and a ribosome by NusA and NusG[19]; and the identification of novel antibacterial drug targets in bacterial RNA polymerase.[20][21][22][23][24][25]
In 1994 Ebright was awarded the American Society of Biochemistry and Molecular Biology Schering-Plough Award for his research on transcription activation.[26] In 1995 he received the Academic Press Walter J. Johnson Prize.[27] In 2013 he received a National Institutes of Health MERIT Award.[28] He was elected as a Fellow of the American Academy of Microbiology in 1996,[29] the American Association for the Advancement of Science in 2004,[30] the Infectious Diseases Society of America in 2011,[31] and the American Academy of Arts and Sciences in 2016.[32]
Ebright has opposed the proliferation of laboratories working on biological weapons agents[33] and has supported the strengthening of biosafety and biosecurity measures to reduce risks of release of biological
Ebright was appointed as a faculty member in the Department of Chemistry at Rutgers University and as a Laboratory Director at the Waksman Institute of Microbiology in 1987.[1] He was co-appointed as an Investigator of the Howard Hughes Medical Institute from 1997 to 2013.[1]
Ebright has performed research on protein-DNA interaction,[3][4][5]transcription initiation,[6][7][8][9][10][11][12]transcription activation,[13][14][15][16][17][18] transcription-translation coupling,[19] and antibacterial drug discovery.[20][21][22][23][24][25] Ebright's research results include the experimental demonstration that amino-acid-base contacts mediate DNA sequence recognition in protein–DNA interaction,[3] the determination of the three-dimensional structural organization of the transcription initiation complex;[6][7][10][11] the demonstration that transcription start-site selection and initial transcription involve a "DNA scrunching" mechanism;[8][9][12] the demonstration that transcription activation can proceed by a "recruitment" mechanism;[13][14][15][17][18] the demonstration that bacterial transcription-translation coupling involves direct physical bridging of RNA polymerase and a ribosome by NusA and NusG[19]; and the identification of novel antibacterial drug targets in bacterial RNA polymerase.[20][21][22][23][24][25]
In 1994 Ebright was awarded the American Society of Biochemistry and Molecular Biology Schering-Plough Award for his research on transcription activation.[26] In 1995 he received the Academic Press Walter J. Johnson Prize.[27] In 2013 he received a National Institutes of Health MERIT Award.[28] He was elected as a Fellow of the American Academy of Microbiology in 1996,[29] the American Association for the Advancement of Science in 2004,[30] the Infectious Diseases Society of America in 2011,[31] and the American Academy of Arts and Sciences in 2016.[32]
Ebright has opposed the proliferation of laboratories working on biological weapons agents[33] and has supported the strengthening of biosafety and biosecurity measures to reduce risks of release of biological